A client diagnosed with Cushing's disease will begin treatment with ketoconazole. What laboratory values should the nurse monitor due to the black box warning?

In the context of a client diagnosed with Cushing's disease being treated with ketoconazole, monitoring AST (aspartate aminotransferase), ALT (alanine aminotransferase), and GGT (gamma-glutamyl transferase) is crucial due to the black box warning associated with the medication. This warning highlights the potential for severe hepatotoxicity, which can manifest as liver injury or failure.

Ketoconazole is known to affect liver function, and alterations in the levels of these liver enzymes can be indicative of such damage. By monitoring AST, ALT, and GGT regularly, healthcare professionals can detect any signs of liver dysfunction early, allowing for timely intervention if necessary. This monitoring is a vital aspect of ensuring the safety and well-being of the patient during treatment with ketoconazole.

While other laboratory values may also be important depending on the patient's overall health and treatment plan, the specific focus on liver enzymes aligns directly with the safety concerns outlined in the black box warning for ketoconazole.